OBJECTIVES: To assess the ability of a multi-biomarker disease activity (MBDA) score to track clinical response in patients with rheumatoid arthritis (RA) treated with different TNF inhibitors. METHODS: The study included 147 patients who had received adalimumab, etanercept, or infliximab for a year or more, during routine clinical care at the University Hospital of Occupational and Environmental Health, Japan. MBDA scores and clinical measures of disease activity were evaluated at baseline and, after 24 weeks (N = 84) and 52 weeks of treatment. Relationships between the changes (∆) in MBDA score and changes in clinical measures or EULAR response categories were evaluated. RESULTS: The median disease activity was 5.7 by DAS28-ESR and 64 by MBDA score at baseline, and decreased significantly with treatment. ∆MBDA scores over 1 year correlated with ∆DAS28-ESR (r = 0.48) and ∆DAS28-CRP (r = 0.46). Linear relationships between ∆MBDA scores and ∆DAS28-ESR or ∆DAS28-CRP were not significantly different between TNF inhibitors. The MBDA scores declined significantly more in good responders (median change: -29) than moderate (-21), and more in moderate than in non-responders (+ 2), by the EULAR criteria. CONCLUSIONS: MBDA scores tracked disease activity and treatment response in patients with RA treated with three TNF inhibitors. The relationships between ∆MBDA scores and ∆DAS28-ESR or ∆DAS28-CRP were consistent across the three TNF inhibitor groups.
OBJECTIVES: To assess the ability of a multi-biomarker disease activity (MBDA) score to track clinical response in patients with rheumatoid arthritis (RA) treated with different TNF inhibitors. METHODS: The study included 147 patients who had received adalimumab, etanercept, or infliximab for a year or more, during routine clinical care at the University Hospital of Occupational and Environmental Health, Japan. MBDA scores and clinical measures of disease activity were evaluated at baseline and, after 24 weeks (N = 84) and 52 weeks of treatment. Relationships between the changes (∆) in MBDA score and changes in clinical measures or EULAR response categories were evaluated. RESULTS: The median disease activity was 5.7 by DAS28-ESR and 64 by MBDA score at baseline, and decreased significantly with treatment. ∆MBDA scores over 1 year correlated with ∆DAS28-ESR (r = 0.48) and ∆DAS28-CRP (r = 0.46). Linear relationships between ∆MBDA scores and ∆DAS28-ESR or ∆DAS28-CRP were not significantly different between TNF inhibitors. The MBDA scores declined significantly more in good responders (median change: -29) than moderate (-21), and more in moderate than in non-responders (+ 2), by the EULAR criteria. CONCLUSIONS:MBDA scores tracked disease activity and treatment response in patients with RA treated with three TNF inhibitors. The relationships between ∆MBDA scores and ∆DAS28-ESR or ∆DAS28-CRP were consistent across the three TNF inhibitor groups.
Authors: Tate M Johnson; Kyle A Register; Cynthia M Schmidt; James R O'Dell; Ted R Mikuls; Kaleb Michaud; Bryant R England Journal: Arthritis Care Res (Hoboken) Date: 2019-11 Impact factor: 4.794
Authors: Christoph Kessel; Angela McArdle; Emely Verweyen; Toni Weinhage; Helmut Wittkowski; Stephen R Pennington; Dirk Foell Journal: Curr Rheumatol Rep Date: 2018-07-14 Impact factor: 4.592
Authors: Marjan Ghiti Moghadam; Femke B G Lamers-Karnebeek; Harald E Vonkeman; Peter M Ten Klooster; Janneke Tekstra; Annemarie M Schilder; Henk Visser; Eric H Sasso; David Chernoff; Willem F Lems; Dirk-Jan van Schaardenburg; Robert Landewe; Hein J Bernelot Moens; Timothy R D J Radstake; Piet L C M van Riel; Mart A F J van de Laar; Tim L Jansen Journal: PLoS One Date: 2018-05-23 Impact factor: 3.240
Authors: Nadia M T Roodenrijs; Maria J H de Hair; Gill Wheater; Mohsen Elshahaly; Janneke Tekstra; Y K Onno Teng; Floris P J G Lafeber; Ching Chang Hwang; Xinyu Liu; Eric H Sasso; Jacob M van Laar Journal: Arthritis Res Ther Date: 2018-11-20 Impact factor: 5.156